JP Patent

JP7697961B2 — 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。

Assigned to Fondation Asile Des Aveugles · Expires 2025-06-24 · 1y expired

What this patent protects

Patent listed against Kerendia.

Drugs covered by this patent

Kerendia (FINERENONE) · Bayer

Patent Metadata

Patent number: JP7697961B2
Jurisdiction: JP
Classification: —
Expires: 2025-06-24
Drug substance claim: No
Drug product claim: No
Assignee: Fondation Asile Des Aveugles
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.